Degradation of adenine nucleotides in the erythrocytes of patients with chronic renal failure.
In chronic renal failure AMP-deaminase operates in the erythrocytes at a much higher velocity than in healthy subjects, with a simultaneous shift from the AMP-adenine-inosine-hypoxanthine pathway (55% and 19%, respectively) to the pathway initiated by AMP-deaminase (45% and 81%, respectively).
Smoleński
R T
RT
Department of Biochemistry, Academic Medical School of Gdańsk, Poland.
Marlewski
M
M
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000227:Adenine Nucleotides / Q000097:blood*; D000243:Adenosine Deaminase / Q000097:blood; D058892:Adenosine Deaminase Inhibitors; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000097:blood; D066298:In Vitro Techniques; D007676:Kidney Failure, Chronic / Q000097:blood*; D012016:Reference Values
D000227:Adenine Nucleotides; D058892:Adenosine Deaminase Inhibitors; D007042:Hypoxanthines; D019271:Hypoxanthine; C010192:9-(2-hydroxy-3-nonyl)adenine; D000243:Adenosine Deaminase; D000225:Adenine